Italian nationwide survey of pharmacologic treatments in diverticular disease: Results from the REMAD registry. Issue 6 (1st July 2019)

• Record Type: Journal Article
• Authors: Cremon, Cesare; Carabotti, Marilia; Cuomo, Rosario; Pace, Fabio; Andreozzi, Paolo; Barbaro, Maria Raffaella; Annibale, Bruno; Barbara, Giovanni
• Is Part Of: United European Gastroenterology journal. Volume 7:Issue 6(2019)
• Page Start: 815
• Page End: 824
• Publication Date: 2019-07-01
• Subjects: Diverticulosis -- management -- pharmacological treatments -- previous diverticulitis -- registry -- symptomatic uncomplicated diverticular disease; Gastroenterology -- Periodicals; Periodicals; 616.33005
• DOI: 10.1177/2050640619845990
• Languages: English
• ISSNs: 2050-6406

Abstract

Abstract : Background: Although diverticular disease is a common condition, its effective treatment is challenging in clinical practice. Objective: The objective of this article is to assess pharmacological management in different clinical settings of diverticular disease and factors associated with treatment using the Italian registry Registro Malattia Diverticolare (REMAD). Methods: At study enrolment, patients were categorised into subgroups: diverticulosis, symptomatic uncomplicated diverticular disease and previous diverticulitis. We registered demographic, clinical and lifestyle factors, quality of life and the use of treatments for diverticular disease in the last year. Logistic regression analysis assessed the association between clinical factors and treatment consumption. Results: A total of 500 of the 1206 individuals included had had at least one treatment for diverticular disease in the last year: 23.6% (166/702) of patients with diverticulosis, 55.9% (165/295) of patients with symptomatic diverticular disease, and 80.9% (169/209) of patients with previous diverticulitis ( p < 0.001). In multivariate analysis, the following factors were significantly associated with treatment use: female gender, family history of colonic diverticula, organic digestive comorbidity and impaired physical quality of life components. Conclusion: Individuals with diverticular disease take medications based on the different clinical settings of disease. We identified different features associated with treatment use in the distinct clinical entities of diverticular disease. ClinicalTrial.gov Identifier: NCT03325829.